Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus ZIPSOR.
LODINE vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
50 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category C
Category C
NSAID
NSAID